Prof. Jintao Liu
Associate Professor
School of Basic Medical Science
Tsinghua University
biography
Jintao Liu is an Associate Professor at Tsinghua University, School of Basic Medical Science. He obtained BS in physics from University of Science and Technology of China, PhD in physics from University of Pittsburgh, and conducted postdoctoral training at University of California San Diego. Dr. Liu and his team study bacterial communities. They use biofilms as model systems, which are densely-packed communities. Using interdisciplinary and quantitative approaches, they focus on developing new approaches to investigate the spatial properties of biofilms, and on uncovering the mechanisms and principles governing their resistance.
Title
Latent DNA damage caused by RNA polymerase stalling underlies the bactericidal potential of ribosomal antibiotics
abstract
Bacteriostatic antibiotics are widely used to suppress bacterial growth, yet their bactericidal potential remains poorly understood. Here we show that three different classes of ribosomal antibiotics—tetracycline, chloramphenicol, and erythromycin—all trigger genome-wide RNA polymerase stalling by disrupting transcription-translation coupling, leading to extensive DNA damage. Using single-cell tracking, we demonstrate that at bacteriostatic concentrations the damage is efficiently resolved by the bacterial DNA repair machinery, thereby masking the underlying lethal capacity of the antibiotics. However, when the repair system is overwhelmed at high doses, or when RecA-mediated repair is genetically disabled or chemically inhibited with small-molecule inhibitor, these antibiotics become potently bactericidal. Our work uncovers a latent genotoxic effect common to the diverse ribosome-targeting antibiotics, and establishes the disruption of RNA polymerase stalling rescue or DNA repair as the key steps to amplify the genotoxicity. This mechanistic insight provides a rational foundation for liberating the bactericidal potential of the large repertoire of bacteriostatic antibiotics, offering new strategies to improve the outcome of therapies and combat antibiotic resistance.
